Browsing by Author HO HAN KIAT

Select a letter below to browse by last name or type
0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z


Showing results 14 to 32 of 32 < previous 
Issue DateTitleAuthor(s)
4-Jun-2012Immobilisation of quantum dots by bio-orthogonal PCR amplification and labelling for direct gene detection and quantitationTian, Q. ; Wong, W.; Xu, Y.; Chan, Y. ; Ho, H.K. ; Pastorin, G. ; Ang, W.H. 
2016Impact of TNF-α (rs1800629) and IL-6 (rs1800795) Polymorphisms on Cognitive Impairment in Asian Breast Cancer PatientsChae J.-W.; Ng T.; Yeo H.L.; Shwe M.; Gan Y.X.; HO HAN KIAT ; Chan A. 
2018Improved Bioavailability of Levodopa Using Floatable Spray-Coated Microcapsules for the Management of Parkinson�s DiseaseBaek J.-S.; Tee J.K. ; Pang Y.Y. ; Tan E.Y.; Lim K.L. ; Ho H.K. ; Loo S.C.J.
Jul-2012Interaction of lapatinib with cytochrome P450 3A5Chan, E.C.Y. ; New, L.S. ; Chua, T.B.; Yap, C.W. ; Ho, H.K. ; Nelson, S.D.
Mar-2013Investigating the role of nucleoside transporters in the resistance of colorectal cancer to 5-fluorouracil therapyPhua, L.C.; Mal, M.; Koh, P.K.; Cheah, P.Y.; Chan, E.C.Y. ; Ho, H.K. 
1-Feb-2010Investigation of the role of the thiazolidinedione ring of troglitazone in inducing hepatotoxicitySaha, S.; New, L.S. ; Ho, H.K. ; Chui, W.K. ; Chan, E.C.Y. 
23-Mar-2012Klotho-beta overexpression as a novel target for suppressing proliferation and fibroblast growth factor receptor-4 signaling in hepatocellular carcinomaPoh, W.; Wong, W.; Ong, H.; Aung, M.O.; Lim, S.G.; Chua, B.T.; Ho, H.K. 
2015Mechanism-based inactivation of CYP450 enzymes: A case study of lapatinibHo H.K ; Chan J.C.Y; Hardy K.D., Chan E.C.Y.
1-Feb-2015Mechanism-based inactivation of CYP450 enzymes: A case study of lapatinibHo, Han Kiat ; Chan, James Chun Yip; Hardy, Klarissa D.; Chan, Eric Chun Yong 
Oct-2010Mechanism-based inactivation of cytochrome P450 3A4 by lapatinibTeng, W.C.; Oh, J.W.; New, L.S. ; Wahlin, M.D.; Nelson, S.D.; Ho, H.K. ; Chan, E.C.Y. 
2015Metabolism-related pharmacokinetic drug-drug interactions with tyrosine kinase inhibitors: Current understanding, challenges and recommendationsTeo Y.L ; Ho H.K ; Chan A 
Sep-2013Nanomaterial scaffolds for stem cell proliferation and differentiation in tissue engineeringZhao, C.; Tan, A.; Pastorin, G. ; Ho, H.K. 
2015Novel arylalkenylpropargylamines as neuroprotective, potent, and selective monoamine oxidase B inhibitors for the treatment of Parkinson's diseaseHuleatt Paul B.; Khoo Mui Ling; Chua Yi Yuan; Tan Tiong Wei; Liew Rou Shen; Balogh Balazs; Deme Ruth; Goloncser Flora; Magyar Kalman; Sheela David P.; HO HAN KIAT ; Sperlagh Beta; Matyus Peter; Chai Li Lin Christina 
Mar-2002Public Awareness of Diabetes Mellitus in SingaporeWee, H.L. ; Ho, H.K. ; Li, S.C. 
15-Dec-2012Pyrrolidinediones reduce the toxicity of thiazolidinediones and modify their anti-diabetic and anti-cancer propertiesSaha, S.; Chan, D.S.Z.; Lee, C.Y.; Wong, W.; New, L.S. ; Chui, W.K. ; Yap, C.W. ; Chan, E.C.Y. ; Ho, H.K. 
30-Oct-2011Reversible time-dependent inhibition of cytochrome P450 enzymes by duloxetine and inertness of its thiophene ring towards bioactivationChan, C.Y.; New, L.S. ; Ho, H.K. ; Chan, E.C.Y. 
Apr-2013Risk of tyrosine kinase inhibitors-induced hepatotoxicity in cancer patients: A meta-analysisTeo, Y.L.; Ho, H.K. ; Chan, A. 
28-Dec-2010Thin films of functionalized multiwalled carbon nanotubes as suitable scaffold materials for stem cells proliferation and bone formationNayak, T.R.; Jian, L. ; Phua, L.C.; Ho, H.K. ; Ren, Y.; Pastorin, G. 
Jan-2014Vascular endothelial growth factor inhibitors and cognitive impairment: Evidence and controversiesNg, T.; Cheung, Y.T.; Ng, Q.S.; Ho, H.K. ; Chan, A.